Infos zu Corona - Aktuelle Informationen zu SARS-CoV-2 : Behandlung/ treatment

Behandlung/ treatment » Bamlanivimab/ Etesevimab (Lilly)

Letzte Änderung: 24.02.2021 um 08:52 Uhr

Weitere frühere Infos zu den Antikörpern von AbCellera/ Eli Lilly unter Behandlung - Antikörper.

Weiterführende Links zum Artikel

BAMLANIVIMAB GEGEN COVID-19? (Hinzugefügt: 24.02.2021 um 08:52 Uhr)
https://www.arznei-telegramm.de/html/2021_02/2102403_01.html
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 (Hinzugefügt: 10.02.2021 um 09:51 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-bamlanivimab-ly-cov555-administered-etesevimab-ly-cov016
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 (Hinzugefügt: 10.02.2021 um 09:51 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19-0
https://www.fda.gov/media/143603/download (Hinzugefügt: 07.02.2021 um 10:18 Uhr)
https://www.fda.gov/media/143603/download
SARS-CoV-2: Forscher finden weitere Mutationen für ein Immunescape (Hinzugefügt: 27.01.2021 um 09:23 Uhr)
https://www.aerzteblatt.de/nachrichten/120542/SARS-CoV-2-Forscher-finden-weitere-Mutationen-fuer-ein-Immunescape
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent (Hinzugefügt: 26.01.2021 um 12:48 Uhr)
https://investor.lilly.com/news-releases/news-release-details/new-data-show-treatment-lillys-neutralizing-antibodies
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 (Hinzugefügt: 26.01.2021 um 09:06 Uhr)
https://science.sciencemag.org/content/early/2021/01/22/science.abf9302.full
Monoclonal antibodies can prevent COVID-19—but successful vaccines complicate their future (Hinzugefügt: 23.01.2021 um 09:11 Uhr)
https://www.sciencemag.org/news/2021/01/monoclonal-antibodies-can-prevent-covid-19-successful-vaccines-complicate-their-future
SARS-CoV-2: Antikörper erzielt primärpräventive Wirkung bei Bewohnern und Mitarbeitern von Pflegeheimen (Hinzugefügt: 23.01.2021 um 09:03 Uhr)
https://www.aerzteblatt.de/nachrichten/120427/SARS-CoV-2-Antikoerper-erzielt-primaerpraeventive-Wirkung-bei-Bewohnern-und-Mitarbeitern-von-Pflegeheimen
Monoclonal Antibody Combo Treatment Reduces Viral Load in Mild-to-Moderate COVID (Hinzugefügt: 22.01.2021 um 09:00 Uhr)
https://www.medscape.com/viewarticle/944488
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial (Hinzugefügt: 22.01.2021 um 08:56 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2775647
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents (Hinzugefügt: 21.01.2021 um 19:21 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented
Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization (EUA) of Bamlanivimab for Coronavirus Disease 2019 (COVID-19) (Hinzugefügt: 11.01.2021 um 19:21 Uhr)
https://www.fda.gov/media/143604/download
An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19 (Hinzugefügt: 07.01.2021 um 05:21 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2774326
Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs (Hinzugefügt: 07.01.2021 um 05:13 Uhr)
https://investor.lilly.com/news-releases/news-release-details/lilly-provides-comprehensive-update-progress-sars-cov-2
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial (Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.lilly.com/news/stories/statement-activ3-clinical-trial-nih-covid19
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 (Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2029849?articleTools=true
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 (Hinzugefügt: 07.01.2021 um 05:12 Uhr)
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033130?articleTools=true

Behandlung/ treatment » Bamlanivimab/ Etesevimab (Lilly)

Mehr zum Thema "Behandlung/ treatment"

Weitere Themen